Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma

Bristol-Myers Squibb shares were down 1.33% to $57.34 at publication. Study CA209-8UT showed nivolumab plus AVD cut risk of progression with a hazard ratio of 0.42 (median PFS not reached) and lower on-study deaths (1.8% vs 3.4% at 36.7 months). Opdivo generated $5.9B in 2025 and the FDA approved oral Sotyktu for psoriatic arthritis in March, providing product and revenue tailwinds despite near-term downward pressure on the stock.

Analysis

Nivolumab’s label expansion behaviorally reallocates physician choice away from niche ADC strategies and toward PD‑1 backbone regimens; that reallocation will pressure ADC-focused peers (Seagen/Takeda) and reduce downstream demand for specialized HSCT services and ADC manufacturing slots. Expect a measured adoption curve — I model 20–30% share shift in the eligible Hodgkin‑like cohort over 12–24 months rather than an immediate strike‑through of incumbents, because payer prior‑authorization and center logistics are rate‑limiters.

Near term (days–months) the stock is sensitive to adoption signals, payer coverage memos, and next quarterly prints from the PD‑1 franchise; over 12–36 months the real value swing will come from confirmatory trial readouts and negotiated net pricing. Tail risks include a regulatory safety surprise or an unfavorable CMS/NCD decision that could compress realized ASPs by 10–25% versus list prices; conversely, durable real‑world safety and grade reduction in total cost of care would materially accelerate uptake.

The market appears to conflate headline labeling with near‑term revenue certainty — a classic mispricing for a diversified pharma where pipeline optionality and margin mix change more slowly. A tactical play that isolates PD‑1 adoption from broader biotech sentiment captures asymmetry: if adoption is steady, multiple expansion is likely; if payers push back, downside should be capped by the company’s non‑oncology cash flows and recently approved oral franchises over the next 12–24 months.

Key Decisions for Investors

• Pair trade (6–12 months): Long BMY equity / Short SGEN (or TAK) equity — target 8–12% relative outperformance, stop if the pair moves against you by 6%. Rationale: isolates benefit of PD‑1 adoption versus ADC exposure; size 2–3% net portfolio exposure.
• Options (12–18 months): Buy BMY Jan 2027 call spread (debit spread) to express asymmetric upside while capping premium — aim for 2–3x potential return vs max premium paid; exit on 30–50% of max profit or at 12 months if unchanged.
• Hedge (0–6 months): Buy a 6–9 month BMY put (protective) sized to 25–35% of your long exposure if you hold the stock through the next two earnings and any payer coverage announcements; this limits one‑off headline risk at a known cost.
• Event trade (days–weeks): If a payer or major hospital system issues a favorable coverage bulletin, convert option spread to outright long stock and tighten stop to 8% — if bulletin is adverse, increase put hedge to 50% of gross long and consider adding the pair short above.